Toremifene FDA Approval Status
FDA Approved: No
Generic name: toremifene
Company: GTx, Inc.
Treatment for: Prevention of Fractures
Toremifene is an investigational oral selective estrogen receptor modulator for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy.
In November 2009, GTx, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for toremifene had not been approved.
Development timeline for toremifene
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.